Safety and Immunogenicity of Combinations of Recombinant Subtype E and B Human Immunodeficiency Virus Type 1 Envelope Glycoprotein 120 Vaccines in Healthy Thai Adults | Zendy

Punnee Pitisuttithum | Zendy; Sorachai Nitayaphan | Zendy; P Thongcharoen | Zendy; Chirasak Khamboonruang | Zendy; Jérôme H. Kim | Zendy; Mark de Souza | Zendy; Thippawan Chuenchitra | Zendy; Robin P. Garner | Zendy; Darawan Thapinta | Zendy; Victoria R. Polonis | Zendy; Silvia RattoKim | Zendy; Penprapa Chanbancherd | Zendy; Joseph Chiu | Zendy; Deborah L. Birx | Zendy; AnneMarie Duliège | Zendy; John G. McNeil | Zendy; Arthur E. Brown | Zendy

Open Access

Safety and Immunogenicity of Combinations of Recombinant Subtype E and B Human Immunodeficiency Virus Type 1 Envelope Glycoprotein 120 Vaccines in Healthy Thai Adults

Author(s) -

Punnee Pitisuttithum,

Sorachai Nitayaphan,

P Thongcharoen,

Chirasak Khamboonruang,

Jérôme H. Kim,

Mark de Souza,

Thippawan Chuenchitra,

Robin P. Garner,

Darawan Thapinta,

Victoria R. Polonis,

Silvia RattoKim,

Penprapa Chanbancherd,

Joseph Chiu,

Deborah L. Birx,

AnneMarie Duliège,

John G. McNeil,

Arthur E. Brown

Publication year - 2003

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/376506

Subject(s) - immunogenicity , virology , medicine , vaccination , immunology , antibody , antigen

Safety and immunogenicity of 2 recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein (gp) 120 vaccines derived from SF2 (subtype B) and CM235 (CRF01_AE, Thai E) were evaluated in 370 Thai adults at low risk of HIV infection. Various doses of CM235 (25, 50, or 100 microg) and SF2 (0, 25, or 50 microg) gp120 were used. Eighty volunteers received placebo. There were no serious adverse events related to vaccination. Binding antibody developed in all vaccine recipients. There was no dose response to CM235 gp120, but a dose response to gp120 SF2 was present. Neutralizing antibodies to subtype E HIV-1 NPO3 and subtype B HIV-1 SF2 developed in 84% and 82% of vaccine recipients, respectively. Lymphoproliferative responses were detected in >95% of vaccine recipients. There was no evidence of antigenic interference in HIV-specific humoral or cellular responses. The gp120 Thai E and SF2 vaccines were safe and immunogenic in combination and could be advanced into phase 3 testing.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research